SEC Form 4 · accession 0001144204-16-077888
Celator Pharmaceuticals Inc · CPXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Dougherty
Officer — Executive Chairman · Director
Period of report
Jan 27, 2016
Accepted (ET)
Jan 29, 2016 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option, Right to BuyF1 | $1.32 | Jan 27, 2016 | A | 75,000 | A | — | Jan 27, 2026 | Common Stock | 75,000 | 75,000 | D |
| Stock Option, Right to BuyF2 | $1.32 | Jan 27, 2016 | A | 17,457 | A | — | Jan 27, 2026 | Common Stock | 17,457 | 17,457 | D |
Explanation of responses
- F1These options vest as follows: (i) 18,750 options vest on January 27, 2017; and (ii) the remaining 56,250 options vest in 11 consecutive quarterly installments of 4,687 shares vest on the 27th day of each April, July, October and January, beginning April 27, 2017 and continuing through October 27, 2019 and one final installment of 4,693 shares on January 27, 2020.
- F2These options vest on the date the Issuer announces analysis of overall survival of Study 301, its Phase 3 clinical study.